GalNAc Monomer for Liver-Targeted Nucleic Acid Drug Delivery

ChangeBridge: Patent Apps - Biotech (C12N)

Published March 26th, 2026

Detected March 27th, 2026

Summary

The USPTO has published a patent application detailing a GalNAc monomer for liver-targeted delivery of small nucleic acid drugs. The application, filed by inventors Zeao Huang et al., describes a compound that enhances drug efficacy through efficient liver targeting.

View original document View source feed page

What changed

This document is a publication of a US patent application (US20260085320A1) by the USPTO. It describes a novel GalNAc monomer comprising a ribose ring or derivative, intended for the liver-targeted delivery of small nucleic acid drugs. The application highlights that conjugates prepared from this compound can achieve efficient liver targeting and enhance drug efficacy, specifically mentioning a compound of formula (I).

While this is a patent application and not a regulatory rule, it signals potential future developments in drug delivery technology. Companies involved in nucleic acid therapeutics, particularly those targeting liver conditions, should be aware of this innovation. There are no immediate compliance obligations or deadlines associated with this patent application publication, but it may influence future research, development, and intellectual property strategies in the pharmaceutical sector.

Source document (simplified)

← USPTO Patent Applications

GALNAC MONOMER COMPRISING RIBOSE RING OR DERIVATIVE STRUCTURE THEREOF AND USE THEREOF IN LIVER-TARGETED DELIVERY OF SMALL NUCLEIC ACID DRUGS

Application US20260085320A1 Kind: A1 Mar 26, 2026

Inventors

Zeao Huang, Gengshen Song, Zhikang Tian, Shuo Yang, Yucheng Wu, Rui Fu

Abstract

The present disclosure provides a GalNAc monomer comprising a ribose ring or a derivative structure thereof and a use thereof in liver-targeted delivery of small nucleic acid drugs. Specifically provided is a compound of formula (I) or a pharmaceutically acceptable salt thereof. The GalNAc-conjugated oligonucleotide prepared from the GalNAc compound provided by the present disclosure can achieve efficient liver-targeted delivery and enhance drug efficacy.